Ajay Kundra
Hematology & Oncology · Everett, WANPI 1649291592
Payments from drug & device makers
What this record shows
This record is dominated by education: $68 of the $68 with a category attached, or 100.0%. Genentech USA, Inc. accounts for 78.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 3 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$53
- Pfizer$14
Across 254 payments — averaging $6022.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$542K
- E.r. Squibb & Sons, L.L.C.$171K
- Roche Products Limited$118K
- Seagen Inc.$107K
- Merck$90K
- F. Hoffmann-la Roche AG$80K
- plus $421K from 12 others
What the payments were for
- Education$68100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $53 |
| Pfizer | 2 | $14 |
How this compares
$68 in reported general payments places this provider in the 10th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 45 | $724,228 |
| XtandiEnzalutamide | 33 | $455,196 |
| Lenalidomide | 21 | $278,669 |
| TagrissoOsimertinib Mesylate | 15 | $224,873 |
| ImbruvicaIbrutinib | 12 | $171,629 |
| Abiraterone Acetate | 74 | $65,334 |
| EliquisApixaban | 29 | $19,322 |
| Imatinib Mesylate | 17 | $2,829 |
| Letrozole | 32 | $839 |
| Dexamethasone | 93 | $801 |
| Tamoxifen Citrate | 26 | $566 |
| Acyclovir | 67 | $559 |
| Prochlorperazine Maleate | 56 | $542 |
| Prednisone | 80 | $384 |
| Olanzapine | 36 | $366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $19,32229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Everett
- Xiaowen WangEverett$33K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.